Compare T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Rex 2X Inverse MSTR Daily Target ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? T-Rex 2X Inverse MSTR Daily Target ETF trades at $3.18 (market cap $88.87M), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 84.6× T-Rex 2X Inverse MSTR Daily Target ETF's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, T-Rex 2X Inverse MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold T-Rex 2X Inverse MSTR Daily Target ETF for 8 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| MSTZ | SYRE | |
|---|---|---|
Market Cap | $88.87M | $7.52B |
Volume | 52,792,380 | 1,441,031 |
Sector | Leveraged / Inverse | Health |
52-Week High | $27.92 | $108.92 |
52-Week Low | $2.29 | $22.18 |
Typical Hold Time | 8 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTZ trades at $2.69 with minimal daily movement (+0.37%). Technical indicators show a bearish bias with moving averages signaling caution, while oscillators remain neutral. The stock lacks available fundamental data for key valuation and profitability metrics, creating uncertainty about its financial health. Recent ETF coverage highlights performance trends but provides limited company-specific insights.
The outlook remains uncertain due to missing financial data and bearish technical signals. Investment opportunity hinges on future earnings visibility and improved technical momentum. Key risks include lack of financial transparency and weak technical positioning that could pressure the stock toward support levels near $2.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
